<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Antigua-Made A</submitter><funding>Chao Family Comprehensive Cancer Center</funding><funding>NCI/NIH</funding><funding>NCI NIH HHS</funding><pagination>871-885</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12380944</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>36(9)</volume><pubmed_abstract>&lt;h4>Purpose&lt;/h4>Utilization of lung cancer screening (LCS) among eligible patients remains low at 16% in 2022. In this systematic review and meta-analysis we assessed the (a) LCS completion rate, and (b) intention to complete LCS, among patients who receive patient decision aids (PDAs).&lt;h4>Methods&lt;/h4>PubMed, Cochrane, Scopus, CINAHL, and Web of Science were searched for articles published in English between 1 January 2011, and 28 February 2023. Two independent reviewers selected randomized controlled trials and prospective cohort studies that reported PDA interventions targeting either LCS completion rate or intention to complete LCS. Quality appraisal and data extraction were performed independently by 2 reviewers using the National Heart, Lung, and Blood Institute quality assessment too</pubmed_abstract><journal>Cancer causes &amp; control : CCC</journal><pubmed_title>Lung cancer screening completion among patients using decision aids: a systematic review and meta-analysis.</pubmed_title><pmcid>PMC12380944</pmcid><funding_grant_id>P30 CA062203</funding_grant_id><funding_grant_id>P30CA062203</funding_grant_id><pubmed_authors>Chen WP</pubmed_authors><pubmed_authors>Ziogas A</pubmed_authors><pubmed_authors>Sadigh G</pubmed_authors><pubmed_authors>Antigua-Made A</pubmed_authors><pubmed_authors>Rashidi A</pubmed_authors><pubmed_authors>Nguyen S</pubmed_authors></additional><is_claimable>false</is_claimable><name>Lung cancer screening completion among patients using decision aids: a systematic review and meta-analysis.</name><description>&lt;h4>Purpose&lt;/h4>Utilization of lung cancer screening (LCS) among eligible patients remains low at 16% in 2022. In this systematic review and meta-analysis we assessed the (a) LCS completion rate, and (b) intention to complete LCS, among patients who receive patient decision aids (PDAs).&lt;h4>Methods&lt;/h4>PubMed, Cochrane, Scopus, CINAHL, and Web of Science were searched for articles published in English between 1 January 2011, and 28 February 2023. Two independent reviewers selected randomized controlled trials and prospective cohort studies that reported PDA interventions targeting either LCS completion rate or intention to complete LCS. Quality appraisal and data extraction were performed independently by 2 reviewers using the National Heart, Lung, and Blood Institute quality assessment too</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Sep</publication><modification>2026-05-10T04:29:23.539Z</modification><creation>2026-04-08T01:29:31.205Z</creation></dates><accession>S-EPMC12380944</accession><cross_references><pubmed>40100526</pubmed><doi>10.1007/s10552-025-01987-4</doi></cross_references></HashMap>